{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:36:47Z","timestamp":1789011407077,"version":"build-2803163510"},"reference-count":44,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Novel agents, including Bruton\u2019s tyrosine kinase inhibitors (BTKi; ibrutinib, acalabrutinib), venetoclax, and phosphatidylinositol 3-kinase inhibitors (PI3Ki; idelalisib, duvelisib), have fundamentally changed the chronic lymphocytic leukemia (CLL) treatment landscape, allowing for a chemotherapy-free paradigm for many. Randomized trials that demonstrated efficacy of these agents in the relapsed\/refractory setting rarely included patients with prior novel agent exposure. Herein, we review available data, including single-arm prospective studies and retrospective cohorts, on outcomes for novel agent approaches after novel agent exposure. We examine data for subsequent treatment options in 3 specific scenarios: (1) progression of disease while receiving BTKi, (2) progression of disease after discontinuation of BTKi for intolerance, and (3) after treatment with venetoclax. Data are most robust for venetoclax-based regimens after progression on BTKi. For patients who experience progression of disease after discontinuation of BTKi for intolerance, venetoclax-based regimens and retreatment with BTKi (depending on severity of initial intolerance) are 2 data-driven options. After frontline venetoclax\/obinutuzumab, subsequent treatment approaches depend on whether patients experience progression of disease during or after discontinuation of their fixed duration frontline regimen and whether venetoclax\/obinutuzumab was discontinued for intolerance. After progression of disease while on venetoclax, we recommend BTKi as second-line therapy. For patients who experience progression after completion or premature discontinuation (because of intolerance) of fixed duration venetoclax\/obinutuzumab, either BTKi or retreatment with venetoclax (with aggressive supportive care if prior intolerance) are reasonable considerations. Subsequent lines of therapy in these scenarios include PI3Ki and consideration of cellular therapies. Finally, clinical trial enrollment for interested patients in any line of therapy is recommended.<\/jats:p>","DOI":"10.1182\/hematology.2020000168","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T04:31:45Z","timestamp":1607142705000},"page":"10-17","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Approaches for relapsed CLL after chemotherapy-free frontline regimens"],"prefix":"10.1182","volume":"2020","author":[{"given":"Lindsey E.","family":"Roeker","sequence":"first","affiliation":[{"name":"CLL Program, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony R.","family":"Mato","sequence":"additional","affiliation":[{"name":"CLL Program, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"25","key":"2020121621263422600_B1","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2020121621263422600_B2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2019-128404","article-title":"ELEVATE TN: phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs O plus chlorambucil (Clb) in patients (Pts) with treatment-naive chronic lymphocytic leukemia (CLL)","volume":"134","author":"Sharman","year":"2019","journal-title":"Blood"},{"issue":"23","key":"2020121621263422600_B3","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"2020121621263422600_B4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"2020121621263422600_B5","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"suppl 2","key":"2020121621263422600_B6","first-page":"86","article-title":"Acalabrutinib vs rituximab plus idelalisib (IdR) or bendamustine (BR) by investigator choice in relapsed\/refractory (RR) chronic lymphocytic leukemia: phase 3 ASCEND study","volume":"37","author":"Ghia","year":"2019"},{"issue":"11","key":"2020121621263422600_B7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"23","key":"2020121621263422600_B8","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2020121621263422600_B9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study","volume":"37","author":"Kater","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020121621263422600_B10","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"2020121621263422600_B11","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"13","key":"2020121621263422600_B12","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"issue":"17","key":"2020121621263422600_B13","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood.2019002841","article-title":"How I manage CLL with venetoclax-based treatments","volume":"135","author":"Wierda","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2020121621263422600_B14","first-page":"2258","article-title":"Utility of PET-CT in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy","volume":"104","author":"Mato","year":"2019"},{"issue":"25","key":"2020121621263422600_B15","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","article-title":"Biology and treatment of Richter syndrome","volume":"131","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"24","key":"2020121621263422600_B16","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"7574","key":"2020121621263422600_B17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"issue":"1","key":"2020121621263422600_B18","doi-asserted-by":"crossref","first-page":"11589","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat Commun"},{"issue":"11","key":"2020121621263422600_B19","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2020121621263422600_B20","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"9","key":"2020121621263422600_B21","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"2020121621263422600_B22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"9","key":"2020121621263422600_B23","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2020121621263422600_B24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"2020121621263422600_B25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood.2018882555","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","volume":"134","author":"Roberts","year":"2019","journal-title":"Blood"},{"issue":"18","key":"2020121621263422600_B26","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2020121621263422600_B27","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients","volume":"28","author":"Mato","year":"2017","journal-title":"Ann Oncol"},{"issue":"14","key":"2020121621263422600_B28","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-19-3815","article-title":"Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy","volume":"26","author":"Mato","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2020121621263422600_B29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41409-018-0207-4","article-title":"Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties","volume":"54","author":"Dreger","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2020121621263422600_B30","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood-2018-01-826008","article-title":"High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies","volume":"132","author":"Dreger","year":"2018","journal-title":"Blood"},{"issue":"26","key":"2020121621263422600_B31","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"key":"2020121621263422600_B32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/hon.71_2629","article-title":"TRANSCEND CLL 004: minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts) with relapsed\/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL)","volume":"37","author":"Siddiqi","year":"2019","journal-title":"Hematol Oncol."},{"issue":"22","key":"2020121621263422600_B33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood.V128.22.58.58","article-title":"Implications of concurrent ibrutinib therapy on CAR T-cell manufacturing and phenotype and on clinical outcomes following CD19-targeted CAR T-cell administration in adults with relapsed\/refractory CLL","volume":"128","author":"Geyer","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621263422600_B34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2019-127509","article-title":"Results from a first-in-human, proof-of-concept phase 1 trial in pretreated B-cell malignancies for Loxo-305, a next-generation, highly selective, non-covalent BTK inhibitor","volume":"134","author":"Mato","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621263422600_B35","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2019-127260","article-title":"Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2020121621263422600_B36","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2020121621263422600_B37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2019-126824","article-title":"Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukemia (CLL): extended follow-up from the E1912 trial","volume":"134","author":"Shanafelt","year":"2019","journal-title":"Blood"},{"issue":"S2","key":"2020121621263422600_B38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hon.56_2629","article-title":"A phase 2 study to assess the safety and efficacy of umbralisib in patients with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K delta inhibitor therapy","volume":"37","author":"Mato","year":"2019","journal-title":"Hematol Oncol"},{"issue":"2","key":"2020121621263422600_B39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2020121621263422600_B40","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood-2019-123930","article-title":"Four-year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (venr) in relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL)","volume":"134","author":"Seymour","year":"2019","journal-title":"Blood"},{"issue":"S1","key":"2020121621263422600_B41","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/01.HS9.0000562928.03733.42","article-title":"Efficacy and safety of ibrutinib in relapsed\/refractory chronic lymphocytic leukemia patients previously treated with venetoclax in the murano study","volume":"3","author":"Greil","year":"2019","journal-title":"HemaSphere."},{"issue":"25","key":"2020121621263422600_B42","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood.2020004782","article-title":"BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax","volume":"135","author":"Lin","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2020121621263422600_B43","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/bjh.15802","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis","volume":"185","author":"Eyre","year":"2019","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2020121621263422600_B44","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1182\/blood-2019-123665","article-title":"Outcomes of ibrutinib (Ibr) therapy in Ibr-na\u00efve patients (pts) with chronic lymphocytic leukemia (CLL) progressing after venetoclax (Ven)","volume":"134","author":"Brown","year":"2019","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/10\/1795075\/hem2020000168c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/10\/1795075\/hem2020000168c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T18:16:35Z","timestamp":1608315395000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/10\/474323\/Approaches-for-relapsed-CLL-after-chemotherapyfree"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000168","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}